The risks named plainly, each one with its mitigation.
A serious investor respects a company that names its own risks. This page does not bury them in a footnote. It states each material risk in the order an investor raises it, sizes it honestly, and pairs it with the specific thing that mitigates it. Self-awareness reads as strength. Concealment reads as naivete. Every figure here reconciles to the same validated model the rest of the section uses.
Each with a mitigation.
The raise funds it directly.
Four granted, not pending.
Gaming and MLB, deployed.
Why the risks are on the table, not under it
The defensible part of this business is already done: four issued US patents and a working, deployed system. What the raise buys is distribution, which is execution risk, not invention risk. That is the lower-risk place to deploy capital, but it is not no-risk, and this page is honest about where the work and the uncertainty actually sit. Reading the risks alongside their mitigations is the point. A risk with a funded, specific answer is a manageable risk.
Go-to-market at scale is unproven beyond the Gaming and Sports Entertainment Group
The proof is a Gaming and Sports Entertainment Group plus two MLB seasons. That establishes the technology and the unit economics. It does not yet establish a repeatable motion for selling to thousands of independent bars and restaurants, which is a different distribution problem with a different cost structure. This is the central risk in the deal, and the company does not claim otherwise.
The use of funds is built around exactly this gap: a sales pipeline, channel partnerships with POS integrators and beverage distributors who already sit in the venue, and an ROI- calculator motion that lets the per-venue economics do the selling rather than a rep. The $33,000 per-venue recovery against a fraction-of-that subscription is the argument, and it is the same in an independent bar as in a Gaming and Sports Entertainment venue.
The five-year plan targets 6,000 venues, which is roughly 3 percent of the serviceable market of about 200,000 liquor-serving venues. A low single-digit share is a non-heroic number; the risk is the path to it, and the path is what this capital builds.
Single-case-study concentration
Today the deployed base is concentrated in the proof venues. One venue type, measured well, is enough to prove the technology and the ROI. It is not enough to prove every venue type, and an investor is right to weight a result that has not yet been repeated across segments. Customer concentration also means the early revenue base depends on a small number of relationships.
Broadening the base across independent bars and restaurants is an explicit objective of the raise, so the concentration shrinks as the funded distribution runs. The MLB deployment across two seasons already shows the system holds outside a single venue type, which is the first evidence that the result travels.
The proof venues demonstrate the system; they are not the business model. The model's value is the recurring base across many venues, and the raise is structured to build exactly that breadth.
The valuation is aggressive against current revenue
The pre-money valuation is set well above current revenue, which rests on roughly $0.4M today. An investor who prices on a revenue multiple of present results will find the number high, and that is a fair objection to raise directly. The valuation is a bet that the data moat matures from emerging to established as the install base scales, and the company says so rather than treating that maturation as already complete.
The valuation is justified by the protected position, not the run rate: four issued patents, a transaction data set a competitor cannot reconstruct, and unit economics that expand predictably once distribution is funded. Lead with the patents, which are the established asset, and treat the data moat as the emerging one.
The exit page presents comparables as a sourced band rather than a single optimistic multiple. The defensible band on today's comparables is roughly 7x to 11x of Year-5 revenue, anchored low by the Olo take-private and high by Samsara's IoT-data premium. Multiples above that are framed as a strategic-acquirer-premium scenario, not the base case. The investor underwrites a range, not a number.
Hardware supply chain at volume
Software scales for free; hardware does not. Building and shipping sensing mats at volume is real operational work with real lead times, component dependencies, and quality control. A software-only competitor does not carry this cost, and a hardware miss can throttle deployment even when demand is there.
Manufacturing and supply are treated as a modeled cost and a modeled risk in the financial plan, not an afterthought, and manufacturing-and-supply readiness is a named bucket in the use of funds. The mat is a one-time sale per venue, so hardware volume scales with venue count rather than with usage. That makes the supply requirement plannable against the pipeline rather than against unpredictable consumption.
Competitive response from a well-funded incumbent
The category includes software incumbents like WISK and BevSpot with mature products and broad install bases. A well-funded incumbent could decide to add hardware through a partnership and attack the real-time-automatic position Klynkz holds. The threat of a bigger player moving in is the objection the moat exists to answer.
The patent fortress is the answer to the legal path. The full-system patent means a similar end-to-end product infringes even if it engineers around the specific mat, and the physics patent has no known workaround for reading RFID near liquids. The data set is the answer to the technical path: even a competitor who licensed around the IP would face a model trained on a transaction history they cannot quickly reproduce.
Copy the machine and you infringe. Copy the intelligence and you need years of installed base. The most likely competitive outcome for a serious incumbent is to license or acquire rather than rebuild, which is the exit thesis stated from the other side.
Key-person dependence
An early-stage company carries key-person risk: the founding team conceived the sensing system and secured the patents, and the loss of a key contributor before the commercial engine is built would set back execution. This is normal at this stage and worth naming rather than glossing.
The defensible asset is already institutionalized: the four patents are issued and owned by the company, and the data set lives in the platform, not in a person's head. For the commercial and capital-formation build, Klynkz works with an engineering and implementation partner that supplies the platform, the raise infrastructure, and the go-to-market engine, which spreads execution capacity beyond any single founder.
Regulatory and securities pathway
This is a private securities offering, and the offering must stay within the bounds of its exemption. The pathway is being finalized with counsel among Reg D 506(b), 506(c), and Reg A+, and until that is confirmed the offering and its solicitation must be conducted carefully. In the expansion verticals, future regulatory requirements, FDA chain-of-custody in medical for example, are a separate, far-out consideration.
The securities pathway is being set with counsel, and the data room's legal section, including a risk-disclosure document and an entity-structure note, is built pathway-agnostic until the recommendation is confirmed. The company will not solicit outside the bounds of the chosen exemption. All projections on the site are labeled forward-looking and carry the risk language compliance requires.
Nothing on this page is an offer to sell or a solicitation to buy securities. Any offering is made only through the formal offering documents under the applicable exemption. [pending source verification: securities-pathway memo to be confirmed with counsel]
The risk register at a glance
The same seven risks, mapped to severity and to the specific mitigation that addresses each. The pattern across the table is consistent: the technology and IP risks are already retired, and the open risks cluster on distribution and scale, which is what the capital is raised to address.
flowchart TB
R["Material risk"] --> A{"Already retired,
or funded by the raise?"}
A -- "Technology" --> T["Retired: deployed and measured"]
A -- "IP defensibility" --> P["Retired: 4 issued patents"]
A -- "Distribution at scale" --> F["Funded: use of funds bucket"]
A -- "Concentration" --> F
A -- "Supply chain" --> F
A -- "Valuation" --> S["Sourced comparable band, 7x-11x"]
A -- "Securities pathway" --> C["Counsel-led, pathway-agnostic"]| Risk | Severity | The mitigation |
|---|---|---|
| Go-to-market at scale | High | The raise directly funds the distribution engine. |
| Single-case concentration | Medium | Diversification across segments is a funded objective. |
| Valuation vs revenue | Medium | Priced on the position; sourced 7x to 11x exit band. |
| Hardware supply chain | Medium | Modeled cost; volume scales with venue count. |
| Competitive response | Low | Patent fortress plus data moat force license-or-buy. |
| Key person | Low | IP and data are institutional; partner adds capacity. |
| Regulatory and securities | Low | Counsel-led pathway; pathway-agnostic data room. |